If you have Hodgkin lymphoma and have been treated with brentuximab vedotin (Adcetris) or are a caregiver of an individual with Hodgkin lymphoma, you can help by completing our survey.
Hodgkin Lymphoma Patients and Caregivers: We need your help!
Lymphoma Canada is preparing a submission to the panCanadian Oncology Drug Review (pCODR) for:
- Brentuximab vedotin (Adcetris) for post-autologous stem cell transplant (post-ASCT) consolidation treatment of patients with Hodgkin Lymphoma at high risk of relapse or progression.
If you have Hodgkin lymphoma and have been treated with brentuximab vedotin (Adcetris) or are a caregiver of an individual with Hodgkin lymphoma, you can help by completing our survey.
Your responses will provide us with the patient and caregiver input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS NEW TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Monday, April 4th and should take 10 minutes of your time.
You may access the survey by clicking on the appropriate link below.
Patient Survey: Experience with brentuximab vedotin (Adcetris) for Hodgkin lymphoma
